Claims:

1. Use of a combination comprising panobinostat, or a pharmaceutically acceptable salt thereof, and bortezomib in the manufacture of a medicament for the treatment of a human patient having multiple myeloma, wherein:

a starting dosage is 20 mg of panobinostat or a pharmaceutically acceptable salt thereof, if the patient has no hepatic impairment;

a starting dosage is 15 mg of panobinostat or a pharmaceutically acceptable salt thereof, if the patient has mild hepatic impairment;

a starting dosage is 10 mg of panobinostat or a pharmaceutically acceptable salt thereof, if the patient has moderate hepatic impairment; and

if the patient has severe hepatic impairment, the combination excludes panobinostat or a pharmaceutically acceptable salt thereof;wherein mild hepatic impairment is bilirubin ≤ 1x the upper limit of the normal range ("ULN") and aspartate aminotransferase ("AST") >1xULN, or bilirubin >1.0 to 1.5x ULN and any amount of AST above ULN is present); wherein moderate hepatic impairment is bilirubin >1.5x to 3.0x ULN and any amount of AST above ULN is present; and

wherein severe hepatic is bilirubin > 3.0x ULN and any amount of AST above ULN is present.

2. The use according to claim 1, wherein the treatment further comprises administering an effective dosage of dexamethasone to the patient once the treatment begins.

3. The use according to claim 1 or claim 2, wherein the multiple myeloma is resistant or refractory to prior treatments.

4. The use according to any one of claims 1-3, wherein the dosage of bortezomib is 1.3 mg/m^2 which is to be administered as an injection.

5. The use according to any one of claims 1-3, wherein the bortezomib is to be administered at a dosage of 0.7 mg/m^2 and wherein the patient has mild hepatic impairment.

6. The use according to any one of claims 3-5, wherein the prior treatment comprised bortezomib or an immunomodulatory agent.

7. The use according to claim 6 wherein the prior treatment comprised both bortezomib and an immunomodulatory agent.

8. The use according to claim 6, wherein the prior treatment comprised a chemotherapeutic agent.

9. Use of panobinostat or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a human patient having multiple myeloma, wherein:

a starting dosage is 20 mg of panobinostat or a pharmaceutically acceptable salt thereof, if the patient has no hepatic impairment;

a starting dosage is 15 mg of panobinostat or a pharmaceutically acceptable salt thereof if the patient has mild hepatic impairment;

a starting dosage is 10 mg of panobinostat or a pharmaceutically acceptable salt thereof, if the patient has moderate hepatic impairment; and

not administering panobinostat or a pharmaceutically acceptable salt thereof if the patient has severe hepatic impairment;

wherein mild hepatic impairment is bilirubin ≤ 1x the upper limit of the normal range ("ULN") and aspartate aminotransferase ("AST") >1xULN, or bilirubin >1.0 to 1.5x ULN and any amount of AST above ULN is present;

wherein moderate hepatic impairment is bilirubin >1.5x to 3.0x ULN and any amount of AST above ULN is present; and

wherein severe hepatic is bilirubin > 3.0x ULN and any amount of AST above ULN is present.

10. The use of claim 9, wherein the treatment further comprises administering an effective dosage of dexamethasone to the patient.

11. The use of claim 9, wherein the multiple myeloma is resistant or refractory to prior treatments.

12. The use of claim 11, wherein the prior treatment comprised bortezomib or an immunomodulatory agent.

13. The use of claim 12, wherein the prior treatment comprised both bortezomib and an immunomodulatory agent.

14. The use of claim 11, wherein the prior treatment comprised a chemotherapeutic agent.

15. The use of claim 9, wherein the treatment further comprises administering bortezomib to the patient.

16. The use of claim 15, wherein bortezomib is to be administered by injection.

17. The use of claim 15 or 16, wherein bortezomib is to be administered at a dosage of 1.3 mg/m^2.

18. The use of claim 15 or 16, wherein the patient has mild hepatic impairment and bortezomib is to be administered at a dosage of 0.7 mg/m^2.

19. The use of claim 15, wherein the treatment further comprises administering dexamethasone to the patient.

20. The use of claim 10, wherein dexamethasone is ro be administered orally.

21. The use of claim 10, wherein the dexamethasone is to be administered at a dosage of 20 mg.